Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

This publication has 27 references indexed in Scilit:

• Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule
  Cancer, 2008
• Correlation of O⁶-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
  Journal of Clinical Oncology, 2008
• The Norton–Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens
  Nature Clinical Practice Oncology, 2006
• Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
  New England Journal of Medicine, 2005
• Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme
  Zeitschrift für Krebsforschung und Klinische Onkologie, 2004
• The anti-angiogenic basis of metronomic chemotherapy
  Nature Reviews Cancer, 2004
• Inhibition of angiogenesis by non-toxic doses of temozolomide
  Anti-Cancer Drugs, 2003
• Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
  British Journal of Cancer, 2003
• A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
  Neuro-Oncology, 2002
• Retinoids Inhibit Human Glioma Cell Proliferation and Migration in Primary Cell Cultures But Not in Established Cell Lines
  Neurosurgery, 2000